By Dean Seal
Orchestra BioMed has gotten the go-ahead from federal regulators to start a study examining BackBeat, its atrioventricular interval modulation therapy for treating hypertension in pacemaker patients.
The biomedical company said Tuesday that the U.S. Food and Drug Administration has granted approval of an investigational device…
Read the full article here
